Send to

Choose Destination
Am J Kidney Dis. 1991 Oct;18(4 Suppl 1):34-7.

Recombinant human erythropoietin in predialysis patients.

Author information

Department of Internal Medicine, University of Iowa College of Medicine, Iowa City 52242.


This report reviews the author's experience and the results of a multicenter study with regard to the use of recombinant human erythropoietin (Epo) in predialysis patients. The data demonstrate that Epo corrects anemia and improves quality-of-life assessment and exercise capacity in patients who are not dialyzed, but who have renal insufficiency. The incidence of hypertension was 22% in the Epo-treated subjects and 19% in the placebo group. Within the Epo-treated group, there appears to be a greater frequency of hypertensive events in those subjects receiving the higher dosages. The concern that Epo might accelerate the deterioration of renal function is not substantiated by several clinical studies.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center